With the requirement of storage rising, manufacturers of storage media are focused on acquiring a bigger market share. This rise is attributed to the space hungry customers and growth of sales in smart phones, cloud environment and data centers. Sony (SNE) is one company focusing in a bigger bite of the growing storage market and also challenging its various competitors like SanDisk and Samsung on various fronts. Sony has a diverse product portfolio and is also into flash memory storage devices.
Since Sony is manufacturer of various devices and most of these devices need primary or secondary storage. Sony�� flash drives and SSD�� suffice the requirement of storage in the devices manufactured by Sony, and also as OEM for various other manufacturers. Forward integration of the flash drives and SSD helps Sony to benefit the sales of these storage drives from in house demand.
Sony Mobile is a subsidiary of Sony, it manufactures Smartphones and this has helped growth sales of storage drives manufactured by Sony. The company is also in no doubt for its mobile products and communication (MP&C) growth.
Top 5 Performing Stocks To Buy For 2015: Document Security Systems Inc (DSS)
Document Security Systems, Inc. (DSS), incorporated on May 30, 1984, develops, markets, secure technologies. The Company specializes in fraud and counterfeit protection for all forms of printed documents and digital information. The Company holds numerous patents for optical deterrent technologies that provide protection of printed information from unauthorized scanning and copying. The Company operates three production facilities, a security and commercial printing facility, a packaging facility and a plastic cards facility, where the Company produces secure and non-secure documents for its customers. The Company licenses its anti-counterfeiting technologies to printers and brand-owners. In addition, the Company has a digital division which provides cloud computing services for its customers, including disaster recovery, back-up and data security services. The Company operates in four segments: DSS Printing Group, DSS Plastics Group, DSS Packaging Group and DSS Digital Group. In June 2013, Document Security Systems Inc announced the closing of its previously announced merger with Lexington Technology Group, Inc. In October 2013, the Company announced that it has acquired two portfolios that will enable DSS to develop protected hardware and peripherals that incorporate core DSS security technologies.
The Company provides document security technology to security printers, corporations, consumer product companies and governments worldwide and for currency, identifications, certifications, travel documents, prescription and medical forms, consumer product and pharmaceutical packaging, and school transcripts. Its products are delivered on paper, plastic, or digitally via its AuthentiGuard DX product suite.
DSS Printing Group
The DSS Printing Group provides secure and commercial printing services for end-user customers along with technical support for the Company�� technology licensees. The division produces a wide array of printed materials such as security paper,! vital records, prescription paper, birth certificates, receipts, manuals, identification materials, entertainment tickets, secure coupons, parts tracking forms, brochures, direct mailing pieces, catalogs, business cards, etc. The division also provides the basis of research and development for its security printing technologies.
DSS Plastics Group
The DSS Plastics Group manufactures laminated and surface printed cards which can include magnetic stripes, bar codes, holograms, signature panels, invisible ink, micro fine printing, guilloche patterns, biometric, radio frequency identification (RFID) and watermarks for printed plastic documents such as identity cards, event badges, and driver�� licenses.
DSS Packaging Group
The DSS Packaging Group produces custom paperboard packaging serving clients in the pharmaceutical, beverage, photo packaging, toy, specialty foods and direct marketing industries, among others. The division incorporates the Company's security technologies into printed packaging to help companies prevent or deter brand and product counterfeiting.
DSS Digital Group
The DSS Digital Group provides data center centric solutions to businesses and governments delivered via the cloud. This division is also develops digital data security technologies based on the Company�� optical deterrent technologies.
The Company competes with Standard Register Company, De La Rue Plc, Sharp, Xerox Canon, Ricoh, Hewlett Packard, Eastman Kodak, NoCopi Technologies, Graphic Security Systems Corporation, RR Donnelley, Canadian printer Quebecor World, Bristol ID, AbNote, LaserCard Corporation and L-1 Identity Solutions, Rock-Tenn Company, Caraustar Industries, Inc., Graphic Packaging Holding Company and Mead Westvaco.
Advisors' Opinion:- [By Susan Decker]
Document Security Systems Inc. (DSS), based in Rochester, New York, is suing Facebook Inc. and LinkedIn Corp. for infringing technology covering online collaboration. The patents were acquired in a reverse merger with Lexington Technology Group Inc., an intellectual property company. The shares have fallen 33 percent since the deal closed on July 1.
Top 5 Prefered Companies To Invest In 2014: Celldex Therapeutics Inc(CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company?s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to tr eat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company?s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Advisors' Opinion:- [By Ben Levisohn]
Acorda has dropped 6.3% to $33.12 today at 2pm, while MannKind has gained 5.1% to $5.37. Vertexs Pharmaceuticals (VRTX) has gained 3.3% to $73.25, Celldex Therapeutics (CLDX) has jumped 2.4% to $27.86 and Gilead Sciences (GILD) has ticked up 0.8% to $63.18.
Top 5 Prefered Companies To Invest In 2014: Hyperion Therapeutics Inc (HPTX)
Hyperion Therapeutics, Inc. (Hyperion), incorporated in November 2006, is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company develops Ravicti (glycerol phenylbutyrate) to treat the prevalent urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company has completed two Phase II trials and one pivotal Phase III trial of Ravicti. The Company�� HE clinical program consists of two trials, which have enrolled patients with cirrhosis. On December 23, 2011, the Company submitted a new drug application (NDA) for Ravicti for the chronic management of UCD in patients aged six years and above based on data from its pivotal Phase III trial in adult patients and the results of two Phase II trials, one in adults and one in pediatric patients aged 6 through 17 years. In June 2013, Hyperion Therapeutics Inc announced that the completion of its acquisition of BUPHENYL (sodium phenylbutyrate) Tablets and Powder from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International, Inc.
In June 2011, the Company completed a 24-month carcinogenicity study of Ravicti in rats. On March 22, 2012, pursuant to an asset purchase agreement (purchase agreement) with Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation, the Company purchased all of the worldwide rights to Ravicti. The Company also has an option to acquire all of Ucyclyd�� worldwide rights in BUPHENYL and AMMONUL (sodium phenylacetate and sodium benzoate) injection.
The Company conducted a pivotal Phase III trial of Ravicti in adult patients 18 years of age or older with UCD. The Company completed a second Phase II trial at five centers in North America in UCD patients aged 6 through 17 years. This trial includes two phases: a two-week, open-label, safety, tolerability, pharmacokinetic characteristics and ammonia control of Ravicti. The Co! mpany enrolled 77 adult and pediatric UCD patients in its two 12-month open-label safety studies, 69 of whom completed the studies. The Company conducted nonclinical genotoxicity and carcinogenicity studies to assess the tumorigenic potential of Ravicti in animals and to assess the relevant risk in humans. The Company is conducting a Phase II multi-center study of patients with cirrhosis and episodic HE.
Advisors' Opinion:- [By Jesse Solomon]
NPS Pharmaceuticals (NPSP), for example, created a drug for treating short bowel syndrome. And Hyperion Therapeutics (HPTX) is developing a drug for hepatic encephalopathy, a decline of brain function that according to the National Institute of Health occurs when the liver is no longer able to remove toxins from the blood. Those stocks are up 20% and 40%, respectively, this year.
- [By Sean Williams]
What: Shares of Hyperion Therapeutics (NASDAQ: HPTX ) , a biopharmaceutical company focused on treatments for orphan diseases and hepatology, rose as much as 10% after receiving orphan drug exclusivity status for Ravicti from the Food and Drug Administration, and exercising an option to acquire two additional urea cycle drugs from Valeant Pharmaceuticals (NYSE: VRX ) .
Top 5 Prefered Companies To Invest In 2014: SP Bancorp Inc.(SPBC)
SP Bancorp, Inc. operates as the holding company for SharePlus Federal Bank that provides community banking products and services to individuals, families, and businesses in the United States. The company offers various deposit products, including noninterest-bearing and interest-bearing demand accounts, savings accounts, money market accounts, and certificates of deposit. Its loan portfolio includes residential mortgage loans secured by residential real estate; commercial real estate and home equity loans, including lines of credit and home improvement loans; consumer loans consisting primarily of automobile loans; and commercial business loans. The company also provides brokerage services for the purchase and sale of non-deposit investment and insurance products through a third-party brokerage arrangement. It provides its services through seven branches, four of which are located near the Bank's headquarters in Plano, Texas; two branches are located in Louisville, Kentuc ky; and one branch is located in Irvine, California. The company was founded in 2010 and is headquartered in Plano, Texas.
Advisors' Opinion:- [By Lisa Levin]
SP Bancorp (NASDAQ: SPBC) shares touched a new 52-week high of $28.90 after the company agreed to be acquired by Green Bancorp for $46.2 million in cash.
No comments:
Post a Comment